industry contributors
Dry Eye Foundation is deeply grateful to the organizations who help make our community work possible!
Sight Sciences
April 2023 - Lead Sponsor, Dry Eye Helpline
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. The company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Scope Ophthalmics
July 2023 - Sponsor, Dry Eye Helpline
Our family has been working within the healthcare sector in Ireland & UK for over 80 years. With this heritage Scope was founded by John and Tom Freyne in 2009.
Scope offers innovative management products for Ocular Surface Disease and Age-Related Macular Degeneration, as well as a well-established food supplement range.
Scope operates in the UK, Ireland, and the USA with a product offering with a track record of successfully helping patients worldwide.
Oyster Point
August 2023 - Charitable contribution, Dry Eye Helpline
We are a biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies to treat ophthalmic disease. We continuously strive to advance breakthrough science and deliver therapies to address the unmet needs of patients and professionals.
Oyster Point, which is now part of Viatris, owns Tyrvaya (varenicline solution) Nasal Spray for dry eye disease.
Tarsus Pharmaceuticals
July 2023 - Charitable contribution
Tarsus is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options. Serving patient needs is our passion; delivering revolutionary treatments is our mission.
We are a company that strives to embody the values of commitment, empowerment, and teamwork.
Tarsus’ treatment for Demodex blepharitis (Xdemvy - Lotilaner solution) was approved in July 2023.